- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Meaningful Impact on Outcomes Demonstrated with De-Escalation Strategy in HER2+/HR– Breast Cancer
June 6th 2021, 5:34pm
A de-escalated course of neoadjuvant therapy of trastuzumab and pertuzumab with or without added weekly paclitaxel for only 12 weeks yielded high response rates and significant survival in patients with HER2-positive, hormone receptor–negative early breast cancer.
Durvalumab Plus Neoadjuvant Chemotherapy Yields Long-Lasting Survival in Early TNBC
June 6th 2021, 5:23pm
The addition of durvalumab to neoadjuvant anthracycline and taxane–based chemotherapy was found to significantly improve survival in patients with early triple-negative breast cancer.
Improved Responses Sustained With Pembrolizumab in Treatment-Naïve Melanoma, But Not in Rechallenged Patients
June 6th 2021, 4:31pm
Patients with stage III melanoma who progressed following placebo-based treatment in the first part of the phase 3 EORTC 1325/KEYNOTE-054 trial and crossed over to receive pembrolizumab post-recurrence derived a 38.8% overall response rate and a 32% overall 3-year progression-free survival rate.
Dr. Tawbi on the Efficacy of Relatlimab/Nivolumab in Advanced Melanoma
June 6th 2021, 4:28pm
Hussein A. Tawbi, MD, PhD, discusses the efficacy of relatlimab plus nivolumab in patients with advanced melanoma.
Targeting CLL1-Positive Cells Shows Efficacy in Early Trial in Pediatric AML
June 6th 2021, 3:10pm
Investigators validated the safety and efficacy of anti-C-type lectin-like molecule-1-based CAR T cells in a small clinical trial of pediatric patients with relapsed/refractory acute myeloid leukemia.
Tafasitamab/Lenalidomide Combo Induces Durable Response in DLBCL
June 6th 2021, 3:00pm
Three-year follow-up data from the phase 2 L-MIND study demonstrated that tafasitamab-cxix in combination with lenalidomide induces sustainable response in relapsed/refractory diffuse large B-cell lymphoma.
Lung Cancer and Leukemia Recap at ASCO 2021: Drs Ed Kim and Anthony Mato
June 6th 2021, 12:00am
OncLive News Network: On Location at ASCO 2021
OncLive sits down with Edward S. Kim, MD, and Anthony R. Mato, MD, on the pivotal studies in lung cancer and leukemia at the 2021 ASCO Annual Meeting.
Selumetinib Response Not Driven by MAPK Expression in Pediatric and AYA Refractory Solid Tumors
June 5th 2021, 10:57pm
Selumetinib did not elicit clinical activity in pediatric and young adult patients with refractory cancers who had actionable mutations in the RAS/RAF/MAPK1/2-ERK pathway.
Liposomal Irinotecan Combo Improves Outcomes for Patients with Biliary Tract Cancer
June 5th 2021, 10:40pm
Data from the phase 2 NIFTY trial demonstrated that liposomal irinotecan in combination with 5-fluorouracil/leucovorin significantly improved progression-free survival and overall survival for patients with metastatic biliary tract cancer whose disease had progressed following first-line line gemcitabine/cisplatin.
Ribociclib/Fulvestrant Maintains Survival Benefit in Postmenopausal HR+ Advanced Breast Cancer, Irrespective of Setting
June 5th 2021, 10:14pm
Ribociclib plus fulvestrant continued to significantly improve overall survival over fulvestrant alone in postmenopausal patients with hormone receptor–positive, HER2-negative advanced breast cancer at almost 5 years of follow-up, irrespective of whether patients received the regimen in the first- or second-line setting.
Frontline Camrelizumab Plus Chemotherapy Improves Survival in Advanced Esophageal Squamous Cell Carcinoma
June 5th 2021, 10:10pm
Camrelizumab in combination with chemotherapy demonstrated improved overall survival and progression-free survival and a manageable safety profile as frontline therapy compared with placebo plus chemotherapy in patients with advanced or metastatic esophageal squamous cell carcinoma.
Venetoclax/Fulvestrant Combo Found to Be Inferior to Fulvestrant Alone in ER+/HER2- Breast Cancer
June 5th 2021, 9:50pm
The combination of venetoclax and fulvestrant failed to improve overall outcomes vs fulvestrant alone in patients with locally advanced or metastatic estrogen receptor–positive, HER2-negative breast cancer who had previously received a CDK4/6 inhibitor.
Palbociclib/Fulvestrant Combo Maintains OS Benefit in HR+ Breast Cancer
June 5th 2021, 8:20pm
At a median follow-up of 73.3 months, investigators in the PALOMA-3 trial have concluded that palbociclib plus fulvestrant maintains a clinically meaningful improvement in overall survival compared with placebo plus fulvestrant for patients with HR-positive, HER2-negative advanced breast cancer.
Dr. Slamon on the Benefit of Ribociclib Plus Fulvestrant in HR+/HER2- Advanced Breast Cancer
June 5th 2021, 8:06pm
Dennis J. Slamon, MD, PhD, discusses the long-term benefit of ribociclib plus fulvestrant in patients with hormone receptor-positive, HER2-negative advanced breast cancer.
Alectinib Fails to Improve OS in ALK-Positive NSCLC
June 5th 2021, 7:17pm
In a final overall survival analysis of the J-ALEX study, patients with non-small cell lung cancer receiving alectinib failed to achieve better results than patients receiving crizotinib.
Tucatinib Plus Trastuzumab/Capecitabine Maintain Survival Benefit in HER2-Positive Breast Cancer
June 5th 2021, 6:41pm
Tucatinib plus trastuzumab and capecitabine maintained and even improved overall survival over placebo in pretreated patients with HER2-positive breast cancer.
Selpercatinib Effective in RET Fusion–Positive NSCLC, Irrespective of Prior Therapies
June 5th 2021, 6:11pm
Treatment with selpercatinib demonstrated consistent efficacy in patients with RET fusion-positive non-small cell lung cancer, regardless of prior treatments.
Single Agent and Combination TG-1701 Yield Promising Clinical Activity in CLL and Other B-Cell Malignancies
June 5th 2021, 6:08pm
TG-1701 demonstrated encouraging clinical and pharmacodynamic activity at all dose levels in patients with B-cell malignancies.
Larotrectinib Elicits Robust Responses in TRK Fusion Cancer
June 5th 2021, 5:31pm
The highly selective, central nervous system-active TRK inhibitor larotrectinib yielded promising response rates in patients with TRK fusion cancer, including in those with CNS metastases at baseline.
Pralsetinib Elicits Durable Anti-Tumor Effects in RET Fusion+ Solid Tumors
June 5th 2021, 4:53pm
Pralsetinib demonstrated robust and durable anti-tumor activity, as well as a tolerable safety profile, in heavily pretreated patients with multiple RET fusion–positive advanced solid tumors.